{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:33:57Z","timestamp":1793068437671,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Bayer"},{"name":"LEO Pharma"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jaad.2017.12.022","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T04:10:57Z","timestamp":1519013457000},"page":"S28-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":307,"special_numbering":"S1","title":["Dupilumab: A review of its use in the treatment of atopic dermatitis"],"prefix":"10.1016","volume":"78","author":[{"given":"Melinda J.","family":"Gooderham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panteha","family":"Eshtiaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2017.12.022_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4,\u00a0Supplement","key":"10.1016\/j.jaad.2017.12.022_bib2","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2017.12.022_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1365-2249.1998.00646.x","article-title":"Effects of anti-IL-4 receptor monoclonal antibody on in\u00a0vitro T cell cytokine levels: IL-4 production by T cells from non-atopic donors","volume":"113","author":"Bullens","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2017.12.022_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaad.2017.12.022_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2017.12.022_bib6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2017.12.022_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2017.12.022_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2017.12.022_bib9","series-title":"DUPIXENT\u00ae [package insert]","year":"2017"},{"key":"10.1016\/j.jaad.2017.12.022_bib10","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.12.022_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/psp4.12136","article-title":"Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4R\u03b1, in atopic dermatitis patients and normal volunteers","volume":"5","author":"Kovalenko","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.jaad.2017.12.022_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2009.308","article-title":"Therapeutic protein-drug interactions and implications for drug development","volume":"87","author":"Huang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2017.12.022_bib13","unstructured":"US Food and Drug Administration: Center for Drug Application and Research. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761055Orig1s000ChemR.pdf. Accessed November 8, 2017."},{"issue":"10013","key":"10.1016\/j.jaad.2017.12.022_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2017.12.022_bib15","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2017.12.022_bib16","article-title":"Diagnosis and management of conjunctivitis for the dermatologist","author":"Gooderham","year":"2017","journal-title":"J Cut Med Surgery"},{"key":"10.1016\/j.jaad.2017.12.022_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.12.022_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National\u00a0Survey of Children's Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.12.022_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4168\/aair.2011.3.2.67","article-title":"The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma","volume":"3","author":"Zheng","year":"2011","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaad.2017.12.022_bib20","unstructured":"US National Library of Medicine: ClinicalTrials.gov. A study to determine the safety and tolerability of dupilumab (REGN668\/SAR231893) in patients aged \u22656 to <18 years with atopic dermatitis (eczema). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02407756?term=NCT02407756&rank=1. Accessed November 10, 2017."},{"key":"10.1016\/j.jaad.2017.12.022_bib21","unstructured":"US National Library of Medicine: ClinicalTrials.gov. A study to assess the long-term safety of dupilumab (REGN668\/SAR231893) administered in patients 6 to <18 year of age with atopic dermatitis (AD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02612454?term=NCT02612454&rank=1. Accessed November 10, 2017."},{"key":"10.1016\/j.jaad.2017.12.022_bib22","unstructured":"US National Library of Medicine: ClinicalTrials.gov. Efficacy and safety of dupilumab in patients \u226512 to <18 years of age, with moderate-to-severe atopic dermatitis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03054428?term=NCT03054428&rank=1. Accessed November 10, 2017."},{"key":"10.1016\/j.jaad.2017.12.022_bib23","unstructured":"US National Library of Medicine: ClinicalTrials.gov. Study of dupilumab auto-injector device when used by patients with atopic dermatitis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03050151?term=NCT03050151&rank=1. Accessed November 10, 2017."},{"key":"10.1016\/j.jaad.2017.12.022_bib24","unstructured":"US National Library of Medicine: ClinicalTrials.gov. A study to assess the efficacy and safety of dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine a (CSA) or for those who cannot take oral CSA\u00a0because it is not medically advisable. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02755649?term=NCT02755649&rank=1. Accessed November 10, 2017."},{"key":"10.1016\/j.jaad.2017.12.022_bib25","unstructured":"US National Library of Medicine: ClinicalTrials.gov. A study to confirm the efficacy and safety of different dupilumab dose\u00a0regimens in adults with atopic dermatitis (AD) (SOLO-Continue). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02395133?term=NCT02395133&rank=1. Accessed November 10, 2017."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217328244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217328244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:44:19Z","timestamp":1759272259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217328244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0190962217328244"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.12.022","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab: A review of its use in the treatment of atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(18)30135-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}